Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Snowballgrowthon Sep 13, 2020 7:07am

62 Views

Post# 31549470

RE:RE:RE:RE:RE:RE:RE:Forbion Capital Fund III C.V. / agreement with Forbion Cap.

drippingsnot wrote: Benedict doesn’t care.
He’s clouded by anger and he can’t see past it.

I see it as cash availabe for future aquisitions - as it will become very useful one day.

if it’s a failure ... it’s the kind of failure I don’t mind. That’s how Goodman rolls !

Benedict wrote the investments in funds had been a failure. The management wrote they get attractive returns.

Facts are facts. What are the annual % returns for funds investments so far ?

Bullboard Posts

Eminent acquires promising Nevada gold project